Chimin(SH:603222)2021-10-28 16:00Revenue and Profit - Q3 2021 revenue was CNY 252,346,994.49, a decrease of 3.64% year-over-year, while year-to-date revenue reached CNY 786,543,185.33, an increase of 29.98%[2] - Net profit attributable to shareholders for Q3 2021 was CNY 39,920,657.00, up 27.78% year-over-year, and year-to-date net profit was CNY 145,054,130.16, a significant increase of 316.37%[2] - Basic earnings per share for Q3 2021 was CNY 0.11, reflecting a 10.00% increase, while year-to-date basic earnings per share reached CNY 0.43, up 290.91%[3] - Total operating revenue for the first three quarters of 2021 reached ¥786,543,185.33, a 30% increase from ¥605,110,242.57 in the same period of 2020[18] - Net profit for the third quarter of 2021 was ¥139,379,458.61, compared to ¥27,842,162.02 in the same quarter of 2020, indicating a significant growth[19] - The company achieved a total comprehensive income of ¥134,559,721.75 in Q3 2021, compared to ¥29,020,640.52 in Q3 2020, indicating substantial growth[20] Assets and Liabilities - The company's total assets as of the end of the reporting period were CNY 2,443,268,425.98, representing a 6.60% increase from the end of the previous year[3] - The total liabilities decreased from RMB 1,200,000,000.00 to RMB 1,023,155,145.09, showing a reduction of about 15%[16] - The total assets increased to 2,302,492,719.27 RMB, up from 2,291,974,753.98 RMB, showing a growth of 10,517,965.29 RMB[27] - The total liabilities rose to 1,256,228,828.85 RMB, compared to 1,245,710,863.56 RMB, indicating an increase of 10,517,965.29 RMB[27] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 152,474,646.59, an increase of 139.75%[2] - The net cash flow from operating activities for the first three quarters of 2021 was ¥152,474,646.59, compared to ¥63,598,423.87 in 2020, representing a 139% increase[22] - The net cash flow from investing activities was -186,883,429.74 RMB, compared to -92,183,005.51 RMB in the previous year, indicating a significant increase in cash outflow for investments[23] - The company raised 908,963,282.22 RMB from financing activities, a substantial increase from 358,584,576.11 RMB in the previous year, demonstrating strong capital inflow[23] - The company reported a net cash inflow from financing activities of 73,646,726.04 RMB, compared to 37,123,376.79 RMB in the previous year, indicating improved financing conditions[23] Shareholder Equity - The equity attributable to shareholders increased by 43.29% to CNY 1,239,083,753.06 compared to the end of the previous year[3] - The total equity attributable to shareholders increased to ¥1,239,083,753.06 in Q3 2021 from ¥864,745,057.76 in Q3 2020, marking a growth of about 43.4%[19] Operational Highlights - The medical device segment significantly contributed to profit growth, with net profit from this segment reaching CNY 113,290,900.00[6] - The company confirmed investment income of CNY 38,261,800.00 from the disposal of equity in Yuncheng Xinyouyi Hospital[6] - Research and development expenses for the third quarter of 2021 were ¥22,108,514.40, compared to ¥17,326,868.63 in the same quarter of 2020, reflecting a 27% increase[19] Legal and Investment Activities - The company has initiated legal proceedings against Neermait for compensation related to the failure of Ezhou Second Hospital to meet performance commitments, with a claim amounting to RMB 75,536,700 plus interest[11] - The company is in the process of repurchasing 84.49% equity in Yuncheng New Friendship Hospital for a total of RMB 135,960,000, with partial payments already made[12]